Multi-peptide CMV-Modified Vaccinia Ankara Vaccine clinical trials
How each study uses Multi-peptide CMV-Modified Vaccinia Ankara Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Multi-peptide CMV-Modified Vaccinia Ankara Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 9
City of Hope Medical Center (8) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Multi-peptide CMV-Modified Vaccinia Ankara Vaccine.
- Dec 2026Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell TransplantPhase 1/2 · City of Hope Medical Center
- Jan 2027CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses Multi-peptide CMV-Modified Vaccinia Ankara Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingPhase 2City of Hope Medical CenterNCT06059391Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell TransplantRecruitingPhase 1/2City of Hope Medical CenterNCT03354728Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin LymphomaRecruitingPhase 1City of Hope Medical CenterNCT05801913Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantActive, not recruitingPhase 1City of Hope Medical CenterNCT03560752Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantActive, not recruitingPhase 2City of Hope Medical CenterNCT02506933Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 2City of Hope Medical CenterNCT04060277Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid MaligCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT03383055Written as CMV-MVA Triplex Vaccine
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnPhase 2City of Hope Medical CenterNCT03438344Written as Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
- Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to CytomegalovirusCompletedPhase 1City of Hope Medical CenterNCT01941056Written as multi-CMV epitope modified vaccinia Ankara vaccine
Given beside what is tested · 2 — Multi-peptide CMV-Modified Vaccinia Ankara Vaccine is usual care or a partner of the new treatment
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT07020533Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaRecruitingPhase 1City of Hope Medical CenterNCT05432635Written as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine